BriaCell's Pivotal Phase 3 Breast Cancer Study Clears Safety Hurdle with Sixth Positive DSMB Review
BCTX sits 16% above its 52-week low of $2.98 on elevated volume (2.3× avg).
Summary
BriaCell's pivotal Phase 3 Bria-ABC study for metastatic breast cancer received its sixth consecutive positive recommendation from the Data Safety Monitoring Board (DSMB). The DSMB found no safety concerns and recommended the study continue without modifications. This is a critical step for the company, which previously disclosed a going concern warning in its March 10-Q. A clean safety profile is essential for the progression of a Phase 3 trial and de-risks the program as it advances under FDA Fast Track designation.
At the time of this announcement, BCTX was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $2.98 to $36.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.